Nxera Pharma Co (TSE:4565) Cyclically Adjusted Revenue per Share: 円0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4565 Nxera Pharma Co Ltd TSE:4565
74 GF Score
Price 円1,105.00
GF Value 円833.48
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Nxera Pharma Co Cyclically Adjusted Revenue per Share?

Nxera Pharma Co TSE:4565 +1.66% 74 Cyclically Adjusted Revenue per Share is 円0.00 as of Jun. 2026. GuruFocus rates TSE:4565 with a GF Score™ of 74/100 and a GF Value™ of 円833.48 (Significantly Overvalued). The stock has 9 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Nxera Pharma Co's adjusted revenue per share for the three months ended in Jun. 2026 was 円0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Nxera Pharma Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 16.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Nxera Pharma Co was 16.90% per year. The lowest was 14.40% per year. And the median was 15.70% per year.

As of today (2026-08-15), Nxera Pharma Co's current stock price is 円1105.00. Nxera Pharma Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was 円0.00. Nxera Pharma Co's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nxera Pharma Co was 42.01. The lowest was 3.75. And the median was 15.45.


Nxera Pharma Co  (TSE:4565) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Nxera Pharma Co was 42.01. The lowest was 3.75. And the median was 15.45.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Nxera Pharma Co Cyclically Adjusted Revenue per Share Related Terms


Nxera Pharma Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Nxera Pharma Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nxera Pharma Co Cyclically Adjusted Revenue per Share Chart

Nxera Pharma Co Annual Data
Trend Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 116.08 135.10 149.58 185.28 202.43

Nxera Pharma Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 197.00 201.08 202.43 208.58 0.00

TSE:4565 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Nxera Pharma Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Cyclically Adjusted PS Ratio falls into.


TSE:4565
74GF Score
Nxera Pharma Co Ltd TSE:4565
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nxera Pharma Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Nxera Pharma Co's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0/113.6000*113.6000
=0.000

Current CPI (Jun. 2026) = 113.6000.

Nxera Pharma Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 11.141 98.000 12.914
201612 17.994 98.400 20.774
201703 27.593 98.100 31.953
201706 41.017 98.500 47.305
201709 37.268 98.800 42.851
201712 14.193 99.400 16.221
201803 8.463 99.200 9.692
201806 10.955 99.200 12.545
201809 12.709 99.900 14.452
201812 14.010 99.700 15.963
201903 40.967 99.700 46.679
201906 25.115 99.800 28.588
201909 34.878 100.100 39.582
201912 25.036 100.500 28.299
202003 14.395 100.300 16.304
202006 17.542 99.900 19.948
202009 23.473 99.900 26.692
202012 58.647 99.300 67.093
202103 14.953 99.900 17.004
202106 23.628 99.500 26.976
202109 5.689 100.100 6.456
202112 162.072 100.100 183.930
202203 13.727 101.100 15.424
202206 16.363 101.800 18.260
202209 74.797 103.100 82.415
202212 81.366 104.100 88.791
202303 11.511 104.400 12.525
202306 14.649 105.200 15.819
202309 40.420 106.200 43.236
202312 87.143 106.800 92.691
202403 51.551 107.200 54.629
202406 90.426 108.200 94.939
202409 103.286 108.900 107.744
202412 76.361 110.700 78.361
202503 73.871 111.100 75.533
202506 93.832 111.700 95.428
202509 74.871 112.000 75.941
202512 86.035 113.000 86.492
202603 73.871 112.700 74.461
202606 0.000 113.600 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円0.00 mean?
Nxera Pharma Co (TSE:4565) has a Cyclically Adjusted Revenue per Share of 円0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nxera Pharma Co and its competitors.
Is Nxera Pharma Co's Cyclically Adjusted Revenue per Share too high?
Nxera Pharma Co's current Cyclically Adjusted Revenue per Share is 円0.00. Overall, Nxera Pharma Co has a GF Score™ of 74/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nxera Pharma Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
Nxera Pharma Co's Cyclically Adjusted Revenue per Share of 円0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Nxera Pharma Co and its competitors. Nxera Pharma Co's current Cyclically Adjusted Revenue per Share is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nxera Pharma Co stock overvalued right now?
Based on GuruFocus' analysis, Nxera Pharma Co (TSE:4565) is currently considered Significantly Overvalued. The stock's GF Value™ is 円833.48, compared to a current price of 円1,105.00 — trading 32.6% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is 円0.00. Nxera Pharma Co's overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Nxera Pharma Co (TSE:4565), the current Cyclically Adjusted Revenue per Share is 円0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Nxera Pharma Co (TSE:4565) Overvalued in 2026?

Based on GuruFocus' analysis, Nxera Pharma Co stock appears to be overvalued. The current stock price of 円1,105.00 is trading 32.6% above its estimated GF Value™ of 円833.48. GuruFocus considers Nxera Pharma Co to be Significantly Overvalued.

Key valuation signals for TSE:4565:

  • Cyclically Adjusted Revenue per Share: 円0.00
  • GF Value™: 円833.48 vs. price of 円1,105.00 (32.6% above fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the TSE:4565 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Nxera Pharma Co Business Description

Other Exchanges SOLTF:USA
Address Midtown East, 9-7-2 Akasaka Minato-ku, Tokyo, JPN, 107-0052
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein Coupled Receptors (GPCRs).
74GF Score

Get the complete analysis for TSE:4565

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,105.00
Price
円833.48
GF Value